Suppr超能文献

慢性阻塞性肺疾病加重期日本患者的临床特征。

Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease.

机构信息

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, Saga Prefecture, 849-8501, Japan.

Clinical Research Center, Saga University Hospital, Saga, Japan.

出版信息

BMC Pulm Med. 2020 Dec 7;20(1):318. doi: 10.1186/s12890-020-01362-w.

Abstract

BACKGROUND

Exacerbations are critical events in chronic pulmonary obstructive disease (COPD). The frequency of COPD exacerbations is associated with the prognosis, including mortality, but no useful biomarker has been established.

METHODS

The present retrospective study investigated 481 COPD patients. Clinical features in the stable period were compared between patients who experienced severe exacerbation (n = 88, 18.3%) and those who never experienced severe exacerbation (n = 393, 81.7%). In the patients who experienced exacerbations, clinical features were also compared between frequent exacerbators (exacerbation rate ≥ 2 times/year, n = 27, 30.7%) and infrequent exacerbators (1 time/year, n = 61, 69.3%).

RESULTS

Compared to COPD patients who never experienced exacerbations, body mass index (BMI), serum albumin, and pulmonary functions were significantly lower, and the cardiovascular disease comorbidity rate, COPD assessment test score, modified Medical Research Council dyspnea scale, and use of long-term oxygen therapy, long-acting β adrenergic agonist therapy, inhaled corticosteroid therapy, and macrolide therapy were significantly higher in COPD patients with exacerbations (all p < 0.01). In patients who experienced exacerbations, frequent exacerbators had significantly lower % forced expiratory volume in 1.0 s and a higher risk of critical exacerbations, percentage of blood eosinophils, history of mechanical ventilation use, and use of long-term oxygen therapy and of macrolide therapy than infrequent exacerbators (all p < 0.01). On multivariate analysis, the percentage of blood eosinophils was the parameter most correlated with exacerbation frequency (β value [95% confidence interval] 1.45 [1.12-1.88], p < 0.01).

CONCLUSION

Blood eosinophil in the stable period is the factor most correlated with the frequency of severe exacerbations.

TRIAL REGISTRATION

The patients in this study was registered retrospectively.

摘要

背景

加重是慢性阻塞性肺疾病(COPD)的关键事件。COPD 加重的频率与预后相关,包括死亡率,但尚未建立有用的生物标志物。

方法

本回顾性研究调查了 481 例 COPD 患者。比较了经历严重加重(n=88,18.3%)和从未经历严重加重(n=393,81.7%)的稳定期患者的临床特征。在经历加重的患者中,还比较了频繁加重者(加重率≥2 次/年,n=27,30.7%)和非频繁加重者(1 次/年,n=61,69.3%)的临床特征。

结果

与从未经历过加重的 COPD 患者相比,经历过加重的患者的体重指数(BMI)、血清白蛋白和肺功能明显较低,心血管疾病合并症发生率、COPD 评估测试评分、改良的医学研究理事会呼吸困难量表以及长期氧疗、长效β肾上腺素能激动剂治疗、吸入皮质类固醇治疗和大环内酯类治疗的使用率明显较高(均 P<0.01)。在经历过加重的患者中,频繁加重者的 1.0 秒用力呼气量百分比明显较低,发生严重加重的风险较高,血嗜酸性粒细胞百分比较高,有机械通气使用史,长期氧疗和大环内酯类治疗的使用率较高(均 P<0.01)。多变量分析显示,血嗜酸性粒细胞百分比是与加重频率最相关的参数(β值[95%置信区间]1.45[1.12-1.88],P<0.01)。

结论

稳定期的血嗜酸性粒细胞是与严重加重频率最相关的因素。

试验注册

本研究中的患者是回顾性注册的。

相似文献

1
Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease.
BMC Pulm Med. 2020 Dec 7;20(1):318. doi: 10.1186/s12890-020-01362-w.
2
Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Int J Chron Obstruct Pulmon Dis. 2015 Mar 10;10:525-33. doi: 10.2147/COPD.S76475. eCollection 2015.
3
Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.
NPJ Prim Care Respir Med. 2017 Apr 17;27(1):25. doi: 10.1038/s41533-017-0029-7.
4
Clinical and Functional Lung Parameters Associated With Frequent Exacerbator Phenotype in Subjects With Severe COPD.
Respir Care. 2017 May;62(5):572-578. doi: 10.4187/respcare.05278. Epub 2017 Mar 7.
5
Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD.
Int J Tuberc Lung Dis. 2014 Dec;18(12):1407-14. doi: 10.5588/ijtld.14.0205.
6
"Frequent exacerbator" is a phenotype of poor prognosis in Japanese patients with chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis. 2016 Feb 3;11:207-16. doi: 10.2147/COPD.S98205. eCollection 2016.
7
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
Lancet Respir Med. 2020 Feb;8(2):158-170. doi: 10.1016/S2213-2600(19)30338-8. Epub 2019 Sep 28.
8
Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
Int J Chron Obstruct Pulmon Dis. 2017 Aug 17;12:2455-2464. doi: 10.2147/COPD.S129321. eCollection 2017.
10
A score to predict short-term risk of COPD exacerbations (SCOPEX).
Int J Chron Obstruct Pulmon Dis. 2015 Jan 27;10:201-9. doi: 10.2147/COPD.S69589. eCollection 2015.

引用本文的文献

1
Chronic Obstructive Pulmonary Disease and the Management of Cardiopulmonary Risk in the UK: A Systematic Literature Review and Modified Delphi Study.
Int J Chron Obstruct Pulmon Dis. 2025 Jun 25;20:2073-2090. doi: 10.2147/COPD.S523865. eCollection 2025.
2
Real-World Treatment Patterns and Patient-Reported Outcomes in Chronic Obstructive Pulmonary Disease in Japan: The REMIND Study.
Adv Ther. 2024 Sep;41(9):3585-3597. doi: 10.1007/s12325-024-02927-5. Epub 2024 Jul 24.
3
The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population.
Int J Chron Obstruct Pulmon Dis. 2023 Aug 15;18:1741-1751. doi: 10.2147/COPD.S417566. eCollection 2023.
5
History of Respiratory Events Prior to a First COPD Diagnosis and Future Exacerbations: A Longitudinal Observational Cohort Database Study in Japan.
Int J Chron Obstruct Pulmon Dis. 2023 Mar 7;18:247-258. doi: 10.2147/COPD.S389297. eCollection 2023.
7
Elevated Peripheral Blood Eosinophils during Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Prevalence and clinical significance.
Sultan Qaboos Univ Med J. 2022 Aug;22(3):339-342. doi: 10.18295/squmj.8.2021.099. Epub 2022 Aug 25.

本文引用的文献

1
Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs.
Int J Chron Obstruct Pulmon Dis. 2019 Dec 10;14:2873-2883. doi: 10.2147/COPD.S228497. eCollection 2019.
2
Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients.
Int J Chron Obstruct Pulmon Dis. 2019 Oct 31;14:2433-2440. doi: 10.2147/COPD.S221466. eCollection 2019.
3
The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries.
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1131-1141. doi: 10.5588/ijtld.19.0397.
5
Exacerbation of COPD.
Am J Respir Crit Care Med. 2018 Dec 1;198(11):P21-P22. doi: 10.1164/rccm.19811P21.
6
Increased serum levels of S100A1, ZAG, and adiponectin in cachectic patients with COPD.
Int J Chron Obstruct Pulmon Dis. 2018 Oct 8;13:3157-3163. doi: 10.2147/COPD.S172996. eCollection 2018.
8
Blood eosinophil levels as a biomarker in COPD.
Respir Med. 2018 May;138:21-31. doi: 10.1016/j.rmed.2018.03.016. Epub 2018 Mar 15.
9
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
10
Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk.
Int J Chron Obstruct Pulmon Dis. 2017 Oct 24;12:3103-3109. doi: 10.2147/COPD.S141646. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验